| 1. |
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG:, Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study., Lancet Oncol, 24 (3): 228-238, 2023.03. |
| 2. |
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y:, Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study., Cancer Med, 12 (6): 6902-6912, 2023.03. |
| 3. |
Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:, Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study., Int J Urol, 30 (2): 139-146, 2023.02. |
| 4. |
Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Validation of user-friendly models predicting extracapsular extension in prostate cancer patients., Asian J Urol, 10 (1): 81-88, 2023.01. |
| 5. |
Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T:, Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate., Eur J Clin Pharmacol, 79 (1): 89-98, 2023.01. |
| 6. |
Nonami A, Matsuo R, Funakoshi K, Nakayama T, Goto S, Iino T, Takaishi S, Mizuno S, Akashi K, Eto M:, Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system., Cytotherapy, 25 (1): 76-81, 2023.01. |
| 7. |
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N:, IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation., BMC Cancer, 22 (1): 1292, 2022.12. |
| 8. |
Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, Kamoto T, Eto M, Habuchi T, Ogawa O, Momozawa Y, Akamatsu S:, Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer., Br J Cancer, 127 (9): 1680-1690, 2022.11. |
| 9. |
Teoh JY, Ng CF, Eto M, Chiruvella M, Capitanio U, Esen T, Zeng G, Lechevallier E, Andonian S, de la Rosette J:, Radical nephroureterectomy for UTUC conferred survival benefits irrespective of age and comorbidities., World J Urol, 40 (11): 2657-2665, 2022.11. |
| 10. |
Kashiwagi E, Shiota M, Lee K, Monji K, Naganuma H, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:, Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide., JMA J, 5 (4): 491-497, 2022.10. |
| 11. |
Kashiwagi E, Shiota M, Naganuma H, Monji K, Imada K, Lee K, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:, Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer., Int J Urol, 29 (10): 1155-1162, 2022.10. |
| 12. |
Igami K, Uchiumi T, Shiota M, Ueda S, Tsukahara S, Akimoto M, Eto M, Kang D:, Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients., Cancer Sci, 113 (9): 3120-3133, 2022.09. |
| 13. |
Furukawa J, Hinata N, Teisima J, Takenaka A, Shiroki R, Kobayashi Y, Kanayama HO, Hattori K, Horie S, Tozawa K, Kato M, Ohyama C, Habuchi T, Kawamorita N, Eto M, Fujisawa M:, Robot-assisted partial nephrectomy with minimum follow-up of 5 years: A multi-center prospective study in Japan., Int J Urol, 29 (9): 1038-1045, 2022.09. |
| 14. |
Komori H, Blas L, Shiota M, Takamatsu D, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence., Int J Urol, 29 (8): 824-829, 2022.08. |
| 15. |
Mizuta Y, Akahoshi T, Eto H, Hyodo F, Murata M, Tokuda K, Eto M, Yamaura K:, Noninvasive Diagnosis of the Mitochondrial Function of Doxorubicin-Induced Cardiomyopathy Using In Vivo Dynamic Nuclear Polarization-Magnetic Resonance Imaging., Antioxidants (Basel), 11 (8): 1454, 2022.07. |
| 16. |
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group:, Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer., Cancer Sci, 113 (7): 2386-2396, 2022.07. |
| 17. |
Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Moriya R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T:, Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis., J Clin Med, 11 (12): 3538, 2022.06. |
| 18. |
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D:, Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study., Lancet Oncol, 23 (6): 768-780, 2022.06. |
| 19. |
Kusunoki M, Nakayama T, Nishie A, Yamashita Y, Kikuchi K, Eto M, Oda Y, Ishigami K:, A deep learning-based approach for the diagnosis of adrenal adenoma: a new trial using CT., Br J Radiol, 95 (1135): 20211066, 2022.06. |
| 20. |
Mutaguchi J, Morooka KI, Kobayashi S, Umehara A, Miyauchi S, Kinoshita F, Inokuchi J, Oda Y, Kurazume R, Eto M:, Artificial intelligence for segmentation of bladder tumor cystoscopic images performed by U-Net with dilated convolution., J Endourol, 36 (6): 827-834, 2022.06. |
| 21. |
Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D:, Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine., Sci Rep, 12 (1): 8535, 2022.05. |
| 22. |
Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M:, An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer., Cancer Sci, 113 (5): 1731-1738, 2022.05. |
| 23. |
Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Eto M:, Validation of models predicting lymph node involvement probability in patients with prostate cancer., Int J Urol, 29 (5): 428-434, 2022.05. |
| 24. |
Blas L, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy., JMA J, 5 (2): 224-229, 2022.04. |
| 25. |
Yamada S, Shiota M, Blas L, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer., Prostate Int, 10 (1): 50-55, 2022.03. |
| 26. |
Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M:, Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 52 (3): 274-280, 2022.03. |
| 27. |
Chikamatsu S, Shiota M, Yamada S, Blas L, Matsumoto T, Kashiwagi E, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer., Prostate Int, 10 (1): 7-13, 2022.03. |
| 28. |
Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Maeda Y, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H:, HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability., Gastroenterology, 162 (3): 799-812, 2022.03. |
| 29. |
Kobayashi M, Fujiyama N, Tanegashima T, Narita S, Yamamoto Y, Fujimoto N, Ueda S, Takeuchi A, Numakura K, Habuchi T, Matsuyama H, Eto M, Shiota M:, Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer., Cancer Immunol Immunother, 71 (3): 727-736, 2022.03. |
| 30. |
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group:, Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy., Int J Clin Oncol, 28 (2): 306-313, 2022.02. |
| 31. |
Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Thomas P, Yoshida M, Koide Y, Umeyama Y, Pietro AD, Uemura H:, Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis., Int J Clin Oncol, 27 (2): 383-395, 2022.02. |
| 32. |
Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto M:, Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer., Andrologia, 54 (1): e14307, 2022.02. |
| 33. |
Harada M, Iida Y, Kotani H, Minami T, Komohara Y, Eto M, Yoshikawa K, Uemura H:, T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma., Cancer Immunol Immunother, 71 (2): 339-352, 2022.02. |
| 34. |
Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy., World J Urol, 41 (1): 43-50, 2022.01. |
| 35. |
Osawa K, Bandara DSV, Nakadate R, Nagao Y, Akahoshi T, Eto M, Arata J:, 2.5-mm articulated endoluminal forceps using a compliant mechanism., Int J Comput Assist Radiol Surg, 18 (1): 1-8, 2022.01. |
| 36. |
Matsumoto T, Shiota M, Yamada S, Blas L, Naganuma H, Lee K, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors., JMA J, 5 (1): 83-90, 2022.01. |
| 37. |
Shiota M, Blas L, Kobayashi S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer., Int J Urol, 29 (1): 26-32, 2022.01. |
| 38. |
Kobayashi H, Shiota M, Sato N, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients., Anticancer Drugs, 33 (1): e541-e547, 2022.01. |
| 39. |
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H:, Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape., Sci Immunol, 6 (65): eabc6424, 2021.11. |
| 40. |
Blas L, Ieiri K, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer., Anticancer Res, 41 (11): 5593-5598, 2021.11. |
| 41. |
Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S:, Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer., Clin Cancer Res, 27 (22): 6164-6173, 2021.11. |
| 42. |
Nagakawa S, Shiota M, Fujimoto N, Yamamoto Y, Blas L, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Matsuyama H, Eto M:, The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study., Urol Oncol, 39 (10): 733.e17-733.e24, 2021.10. |
| 43. |
Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimoto N, Noguchi M:, Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan., Int J Urol, 28 (10): 1008-1011, 2021.10. |
| 44. |
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group:, Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer., Cancer Sci, 112 (9): 3616-3626, 2021.09. |
| 45. |
Chikamatsu S, Shiota M, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database., Int J Urol, 28 (9): 927-935, 2021.09. |
| 46. |
Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K:, Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models., Cancer Immunol Immunother, 70 (9): 2503-2515, 2021.09. |
| 47. |
Kawano T, Tachibana Y, Inokuchi J, Kang JH, Murata M, Eto M:, Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer., Int J Mol Sci, 22 (17): 9276, 2021.08. |
| 48. |
Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y:, Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis., Anticancer Res, 41 (8): 4101-4115, 2021.08. |
| 49. |
Blas L, Shiota M, Yamada S, Ieiri K, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer., Anticancer Res, 41 (8): 3885-3889, 2021.08. |
| 50. |
Blas L, Onozawa M, Shiota M, Hinotsu S, Sakamoto S, Kitagawa Y, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old., Cancer Sci, 112 (8): 3074-3082, 2021.08. |
| 51. |
Iwamoto C, Ohuchida K, Shinkawa T, Okuda S, Otsubo Y, Okumura T, Sagara A, Koikawa K, Ando Y, Shindo K, Ikenaga N, Nakata K, Moriyama T, Miyasaka Y, Ohtsuka T, Eto M, Akashi K, Nakamura M:, Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression., Cancer Lett, 512: 15-27, 2021.08. |
| 52. |
Shiota M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M:, The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer., Pharmacogenomics J, 21 (4): 440-445, 2021.08. |
| 53. |
Koura M, Shiota M, Ueda S, Matsumoto T, Kobayashi S, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic impact of prior local therapy in castration-resistant prostate cancer., Jpn J Clin Oncol, 51 (7): 1142-1148, 2021.07. |
| 54. |
Matsumoto T, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study., Prostate Int, 9 (2): 96-100, 2021.06. |
| 55. |
Kiyozawa D, Kohashi K, Takamatsu D, Yamamoto T, Eto M, Iwasaki T, Motoshita J, Shimokama T, Kinjo M, Oshiro Y, Yonemasu H, Oda Y:, Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity., Hum Pathol, 112: 48-58, 2021.06. |
| 56. |
Machidori A, Shiota M, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Eto M:, Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors., Urol Oncol, 39 (6): 365.e1-365.e7, 2021.06. |
| 57. |
Kobayashi S, Mutaguchi J, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M:, Clinical advantages of robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score-matched comparative analysis., Int J Urol, 28 (6): 630-636, 2021.06. |
| 58. |
Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group., Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma., J Geriatr Oncol, 12 (5): 834-837, 2021.06. |
| 59. |
Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:, Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer., Front Oncol, 11: 697955, 2021.05. |
| 60. |
Shiota M, Sumikawa R, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database., Int J Urol, 28 (5): 584-591, 2021.05. |
| 61. |
Quinn DI, Ng CF, Grande E, Kwon TG, Linke R, Lee JL, Rosbrook B, Thakur MN, Eto M, Gross-Goupil M:, ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups., ESMO Open, 6 (3): 100-105, 2021.04. |
| 62. |
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M, Urological Oncology Group Juog J:, Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients., Cancer Sci, 112 (4): 1524-1533, 2021.04. |
| 63. |
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators:, Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma., N Engl J Med, 384 (14): 1289-1300, 2021.04. |
| 64. |
Hinata N, Shiroki R, Tanabe K, Eto M, Takenaka A, Kawakita M, Hara I, Hongo F, Ibuki N, Nasu Y, Teishima J, Kawai N, Kawauchi A, Kondo T, Kawamorita N, Oyama C, Horie S, Shimbo M, Kato M, Kanayama H, Koito Y, Fujisawa M; Japanese Society of Endourology:, Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study., Int J Urol, 28 (4): 382-389, 2021.04. |
| 65. |
Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M:, Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer., In Vivo, 35 (2): 1101-1108, 2021.03. |
| 66. |
Yamashita T, Shiota M, Machidori A, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer., Cancer Invest, 39 (3): 251-256, 2022.06. |
| 67. |
Naganuma H, Miike K, Ohmori T, Tanigawa S, Ichikawa T, Yamane M, Eto M, Niwa H, Kobayashi A, Nishinakamura R:, Molecular detection of maturation stages in the developing kidney., Dev Biol, 470: 62-73, 2021.02. |
| 68. |
Shiota M, Narita S, Habuchi T, Eto M:, Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer., Pharmacogenomics J, 21 (1): 102-105, 2021.02. |
| 69. |
Takahashi R, Takei M, Namitome R, Yamaguchi O, Eto M:, Symptoms and noninvasive test parameters that clinically differentiate detrusor underactivity from bladder outlet obstruction without a pressure-flow-based diagnosis in men with lower urinary tract symptoms., Neurourol Urodyn, 40 (1): 303-309, 2022.01. |
| 70. |
Matsumoto T, Shiota M, Uchiumi T, Ueda S, Tsukahara S, Toshima T, Matsumoto S, Noda N, Eto M, Kang D:, Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men., Int J Urol, 28 (1): 40-46, 2021.01. |
| 71. |
Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, Ueda S, Ushijima M, Nagakawa S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Oda Y, Eto M:, Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression., Cancer Sci, 112 (1): 323–330, 2021.01. |
| 72. |
Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N:, Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events., Sci Rep, 11 (1): 1324, 2021.01. |
| 73. |
Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group., Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma., J Geriatr Oncol, S1879-4068 (20): 30534-30538, 2020.12. |
| 74. |
Masuda T, Nonami A, Tanaka F, Ando Y, Eto M, Mimori K:, A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer., Breast J, 26 (12): 2420-2423, 2020.12. |
| 75. |
Shiota M, Machidori A, Abe T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Yokomizo A, Naito S, Eto M:, Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide., Int J Urol, 27 (12): 1109-1115, 2020.12. |
| 76. |
Ieiri K, Shiota M, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Iwai H, Shiga KI, Yokomizo A, Yoshitake T, Shioyama Y, Ishigami K, Terashima H, Eto M:, The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?, Urol Oncol, 38 (12): 931.e1-931.e7, 2020.12. |
| 77. |
Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M:, The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study., Int J Clin Oncol, 25 (12): 2107-2114, 2020.12. |
| 78. |
Mizuta Y, Akahoshi T, Guo J, Zhang S, Narahara S, Kawano T, Murata M, Tokuda K, Eto M, Hashizume M, Yamaura K:, Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K/Akt pathway in endothelial cells., Stem Cell Res Ther, 11 (1): 508, 2020.11. |
| 79. |
Sato N, Shiota M, Shiga KI, Kashiwagi E, Takeuchi A, Inokuchi J, Yokomizo A, Naito S, Eto M:, Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy., Cancer Invest, 38 (10): 559-564, 2020.11. |
| 80. |
Shiota M, Endo S, Fujimoto N, Tsukahara S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:, Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy., Urol Oncol, 38 (11): 849.e11-849.e18, 2020.11. |
| 81. |
de la Rosette J, Laguna P, Álvarez-Maestro M, Eto M, Mochtar CA, Albayrak S, Mendoza-Valdes A, Ong TA, Khadgi S, Al-Terki A, Bolton D, Gomez R, Klotz L, Kulkarni S, Tanguay S, Gravas S; Société Internationale d’Urologie Board of Directors:, Cross-continental comparison of safety and protection measures amongst urologists during COVID-19., Int J Urol, 27 (11): 981-989, 2020.11. |
| 82. |
Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, Oda Y:, The SWI/SNF Chromatin-Remodeling Complex Status in Renal Cell Carcinomas With Sarcomatoid or Rhabdoid Features., Virchows Arch, 477 (5): 651-660, 2020.11. |
| 83. |
Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, Shinohara N, Asano T:, Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study., Jpn J Clin Oncol, 50 (11): 1313-1320, 2020.10. |
| 84. |
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:, Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision., Int J Urol, 27 (9): 702-709, 2020.09. |
| 85. |
Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T, Eto M:, High-throughput Screen Identifies 5-HT Receptor as a Modulator of AR and a Therapeutic Target for Prostate Cancer., Prostate, 80 (11): 885-894, 2020.08. |
| 86. |
Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group, Fukuda H:, Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma., Cancer Sci, 111 (7): 2460–2471, 2020.07. |
| 87. |
Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M:, Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer., Cancer Immunol Immunother, 69 (7): 1155-1163, 2020.07. |
| 88. |
Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M:, Surgical Navigation Improves Renal Parenchyma Volume Preservation in Robot-Assisted Partial Nephrectomy: A Propensity Score-matched Comparative Analysis., J Urol, 204 (1): 149-156, 2020.07. |
| 89. |
Takahashi R, Kimoto Y, Maki T, Eto M:, Postinjury Bladder Overdistension Deteriorates the Lower Urinary Tract's Storage Function in Patients with Spinal Cord Injury., Urol Int, 104 (7-8):604-609, 2020.06. |
| 90. |
Kashiwagi E, Abe T, Kinoshita F, Ushijima M, Masaoka H, Shiota M, Netto GJ, Eto M, Miyamoto H:, The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator., Am J Transl Res, 12(6): 3033–3045, 2020.06. |
| 91. |
Takahashi R, Sumino Y, Miyazato M, Nishii H, Oshiro T, Mimata H, Saito S, Yoshida M, Eto M:, Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients With Benign Prostatic Hyperplasia (KYU-PRO Study)., Urol Int, 104(7-8): 587-593, 2020.06. |
| 92. |
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:, Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper., Int J Urol, 27 (5): 362-368, 2020.05. |
| 93. |
Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K:, Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial., Cancer Immunol Immunother, 69 (5): 847-857, 2020.05. |
| 94. |
Kiyozawa D, Takamatsu D, Kohashi K, Kinoshita F, Ishihara S, Toda Y, Eto M, Oda Y:, Programmed Death Ligand 1/indoleamine 2,3-dioxygenase 1 Expression and Tumor-Infiltrating Lymphocyte Status in Renal Cell Carcinoma With Sarcomatoid Changes and Rhabdoid Features., Hum Pathol, 101: 31-39, 2020.04. |
| 95. |
Shiota M, Onozawa M, Hinotsu S, Eto M, Naito S, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database., Int J Urol, 27 (4): 313-318, 2020.04. |
| 96. |
Namitome R, Takei M, Takahashi R, Kikutake C, Yokomizo A, Yamaguchi O, Eto M:, A Prediction Model of Detrusor Underactivity Based on Symptoms and Noninvasive Test Parameters in Men with Lower Urinary Tract Symptoms: An Analysis in a Large Group of Patients Undergoing Pressure-flow Studies., J Urol, 203 (4): 779-785, 2020.04. |
| 97. |
Kashiwagi E, Imada K, Abe T, Kinoshita F, Monji K, Shiota M, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Thick perirenal fat predicts the growth pattern of renal cell carcinoma., Kidney Cancer, 4 (1): 41-48, 2020.03. |
| 98. |
Kashiwagi E, Shiota M, Masaoka H, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer., Prostate Int, 8 (1) :22-26, 2020.03. |
| 99. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study., Anticancer Drugs, 31 (3): 298-303, 2020.03. |
| 100. |
Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M:, Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101., Cancer Sci, 111 (3): 907–923, 2020.03. |
| 101. |
Mitsui R, Lee K, Uchiyama A, Hayakawa S, Kinoshita F, Kajioka S, Eto M, Hashitani H:, Contractile elements and their sympathetic regulations in the pig urinary bladder: a species and regional comparative study., Cell Tissue Res, 379 (2): 373-387, 2020.02. |
| 102. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel., Anticancer Res, 40 (1): 335-339, 2020.01. |
| 103. |
Tanaka M, Irie S, Nakagawa K, Nishimatsu H, Inokuchi J, Eto M:, Nonischemic or Ischemic Laparoscopic Partial Nephrectomy Using a Newly Developed Hybrid Energy Device in a Porcine Model., J Endourol, 34 (1): 82-87, 2020.01. |
| 104. |
Hirata Y, Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer., Prostate Int, 7 (4): 166-170, 2019.12. |
| 105. |
Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:, Corrigendum to: Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program., Jpn J Clin Oncol, 49 (11): 1067, 2020.12. |
| 106. |
Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG):, Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma., J Urol, 202 (6): 1127-1135, 2019.12. |
| 107. |
Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer., Urol Oncol, 37 (11): 813.e21-813.e26, 2019.11. |
| 108. |
Kashiwagi E, Imada K, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M:, Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer., Andrologia, 51 (9): e13354, 2019.10. |
| 109. |
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G:, Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses., Int J Clin Oncol, 24 (9): 1089-1098, 2019.09. |
| 110. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study., Cancer Chemother Pharmacol, 84 (3): 561-566, 2019.09. |
| 111. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study., Anticancer Res, 39 (8): 4411-4414, 2019.08. |
| 112. |
Akitake M, Yamaguchi A, Shiota M, Imada K, Tatsugami K, Yokomizo A, Naito S, Eto M:, Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer., Anticancer Res, 39 (8): 4325-4328, 2019.08. |
| 113. |
Kobayashi S, Cho B, Huaulmé A, Tatsugami K, Honda H, Jannin P, Hashizumea M, Eto M:, Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy., Int J Comput Assist Radiol Surg, 14 (8): 1449-1459, 2019.08. |
| 114. |
Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H:, Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity., Clin Cancer Res, 25 (15): 4808-4819, 2019.08. |
| 115. |
Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM:, TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease., Mol Cancer Res, 17 (8): 1613-1626, 2019.08. |
| 116. |
Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:, Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program., Jpn J Clin Oncol, 49 (8): 772-779, 2019.08. |
| 117. |
Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M:, Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy., Prostate, 79 (10): 1147-1155, 2019.07. |
| 118. |
Hiraki Y, Okamoto D, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Fujita N, Eto M, Kinoshita F, Honda H:, Papillary renal cell carcinoma with massive hematoma mimicking hemangioma., Radiol Case Rep, 14 (8): 1003-1006, 2019.06. |
| 119. |
Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer., Anticancer Res, 39 (6): 3191-3195, 2019.06. |
| 120. |
Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y:, MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma., Cancer Sci, 110 (6): 1897-1908, 2019.06. |
| 121. |
Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men., Clin Genitourin Cancer, 17 (3): e387-e393, 2019.06. |
| 122. |
Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer:, Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma., Cancer Sci, 110 (6): 1820-1828, 2019.06. |
| 123. |
Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study., Jpn J Clin Oncol, 49 (6): 506-514, 2019.06. |
| 124. |
Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men., Cancer Chemother Pharmacol, 83 (5): 933-938, 2019.05. |
| 125. |
Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H:, Overview of current and future systemic therapy for metastatic renal cell carcinoma., Jpn J Clin Oncol, 49 (5): 395-403, 2019.05. |
| 126. |
Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, Eto M:, Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle., Low Urin Tract Symptoms, 11 (2): O209-O217, 2019.04. |
| 127. |
Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ:, Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale., Future Oncol, 15 (9): 929-941, 2019.03. |
| 128. |
Shiota M, Namitome R, Kobayashi T, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer., Int J Urol, 26 (3): 426-428, 2019.03. |
| 129. |
Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer., Urol Oncol, 37 (3): 180.e19-180.e24, 2019.03. |
| 130. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study., Med Oncol, 36 (4): 32, 2019.02. |
| 131. |
Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M:, Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone., JAMA Netw Open, 2 (2): e190115, 2019.02. |
| 132. |
Murakami Y, Naganuma H, Tanigawa S, Fujimori T, Eto M, Nishinakamura R:, Reconstitution of the embryonic kidney identifies a donor cell contribution to the renal vasculature upon transplantation., Sci Rep, 9 (1): 1172, 2019.02. |
| 133. |
Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K:, Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment., Cancer Immunol Immunother, 68 (2): 201-211, 2019.02. |
| 134. |
Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H:, Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan., Int J Urol, 26 (2): 202-210, 2019.02. |
| 135. |
Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy., Front Oncol, 8: 635, 2018, 2018.12. |
| 136. |
Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI:, Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial., Ann Oncol 29, 29 (12): 2371-2378, 2018, 2018.12. |
| 137. |
Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T:, Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan., Clin Genitourin Cancer, 16 (6): e1201-e1214, 2018, 2018.12. |
| 138. |
Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer., Andrologia, 50 (10): e13119, 2018, 2018.12. |
| 139. |
Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:, Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy., Mol Clin Oncol 9 (5): 575-581, 2018, 9 (5): 575-581, 2018, 2018.11. |
| 140. |
Takahashi R, Kimoto Y, Eto M:, Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury., Neurourol Urodyn, 37 (8): 2625-263, 2018, 2018.11. |
| 141. |
Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y:, Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor., J Cancer, 9 (23): 4440-4448, 2018, 2018.10. |
| 142. |
Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants., Cancer Sci, 109 (10): 3224-3234, 2018, 2018.10. |
| 143. |
Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone., Prostate Int, 6 (3): 104-109,2018, 2018.09. |
| 144. |
Inoue M, Okamura K, Kitaoka C, Kinoshita F, Namitome R, Nakamura U, Shiota M, Goto K, Ohtsubo T, Matsumura K, Oda Y, Eto M, Kitazono T:, Metyrapone-responsive ectopic ACTH-secreting pheochromocytoma with a vicious cycle via a glucocorticoid-driven positive-feedback mechanism., Endocr J, 65 (7): 755-767, 2018, 2018.07. |
| 145. |
Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:, Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget, 9 (55): 30587-30593, 2018, 2018.07. |
| 146. |
Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:, Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer., Anticancer Res, 38 (7): 4115-4121, 2018, 2018.07. |
| 147. |
Akitake M, Kiyoshima K, Yokomizo A, Shiga K, Koga H, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Yamaguchi A, Eto M:, A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases., Mol Clin Oncol, 8 (6): 785-790, 2018, 2018.06. |
| 148. |
Morizane S, Honda M, Fukasawa S, Komaru A, Inokuchi J, Eto M, Shimbo M, Hattori K, Kawano Y, Takenaka A:, Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan., Int J Clin Oncol, 23 (3): 568-575, 2018, 2018.06. |
| 149. |
Reix B, Bernhard JC, Patard JJ, Bigot P, Villers A, Suer E, Vuong NS, Verhoest G, Alimi Q, Beauval JB, Benoit T, Nouhaud FX, Lenormand C, Hamidi N, Cai J, Eto M, Larre S, El Bakhri A, Ploussard G, Hung A, Koutlidis N, Schneider A, Carrouget J, Droupy S, Marchal S, Doerfler A, Seddik S, Matsugasumi T, Orsoni X, Descazeaud A, Pfister C, Bensalah K, Soulie M, Gill I, Flamand V; Kidney Cancer group of the CCAFU:, Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR., Prog Urol, 28 (3): 146-155, 2018, 2018.03. |
| 150. |
Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer., J Urol, 199 (3): 734-740, 2018, 2018.03. |
| 151. |
Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol, 25 (2): 112-120, 2018, 2018.02. |
| 152. |
Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y:, Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro., Oncoimmunology, 7 (4): e1415687, 2018, 2018.01. |
| 153. |
Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M:, Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study)., Low Urin Tract Symptoms, 10 (1): 76-83, 2018, 2018.01. |
| 154. |
Fujimoto N, Kubo T, Hisaoka M, Udo K, Yokomizo A, Shibuya T, Wakeda H, Nishihara K, Moriya R, Iwakuma K; Kyushu Cooperative Urological Research Group:, Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan., Int J Urol, 25 (1): 61-67, 2018, 2018.01. |
| 155. |
Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association., Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 47 (12): 1162-1169, 2017, 2017.12. |
| 156. |
Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S; Japan Public Health Center-based Prospective Study Group:, Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study., Int J Cancer, 141 (12): 2480-2488, 2017, 2017.12. |
| 157. |
Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, Matsushima Y, Shiota M, Eto M, Kang D:, Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity., Oncogenesis, 6 (11): 397, 2017, 2017.11. |
| 158. |
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S:, Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A., World J Urol, 35 (11): 1737-1744, 2017, 2017.11. |
| 159. |
Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer., Anticancer Res, 37 (10): 5631-5637, 2017, 2017.10. |
| 160. |
Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M:, Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models., Cancer Sci, 108 (10): 1974-1984, 2017, 2017.10. |
| 161. |
Yamaguchi K, Inoue T, Habuchi T, Inokuchi J, Yokomizo A, Eto M, Kanayama HO:, An In Vitro Study of a New Device: Evaluation of Novel Wide-Angle Lens Flexible Cystoscope Using Phantom Bladder Model., J Endourol, 31 (10): 1073-1078, 2017, 2017.10. |
| 162. |
Masaoka H, Gallus S, Ito H, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Aldehyde Dehydrogenase 2 Polymorphism Is a Predictor of Smoking Cessation., Nicotine Tob Res, 19 (9): 1087-1094, 2017, 2017.09. |
| 163. |
Masaoka H, Ito H, Yokomizo A, Eto M, Matsuo K:, Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan., Cancer Sci
, 108 (8): 1673-1680, 2017, 2017.08. |
| 164. |
Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I:, Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment., Ann Oncol, 28 (8): 2038-2039, 2017, 2017.08. |
| 165. |
Inokuchi J, Eto M, Hara T, Fujimoto H, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C; Cancer Registration Committee of the Japanese Urological Association:, Impact of lymph node dissection on clinical outcomes during nephroureterectomy in patients with clinically node-negative upper urinary tract urothelial cancer: subanalysis of a multi-institutional nationwide case series of the Japanese Urological Association., Jpn J Clin Oncol, 47 (7): 652-659, 2017, 2017.07. |
| 166. |
Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study., Jpn J Clin Oncol, 47 (7): 639-646, 2017, 2017.07. |
| 167. |
Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Koga H, Yamaguchi A, Naito S, Eto M:, Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy., Jpn J Clin Oncol, 47 (5): 453-457, 2017, 2017.05. |
| 168. |
Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Eto M:, The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer., Ann Surg Oncol, 24 (5): 1443-1450, 2017, 2017.05. |
| 169. |
Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer., Endocr Relat Cancer, 24 (4): 171-180, 2017, 2017.04. |
| 170. |
Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T:, A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder., Ann Oncol, 28 (4): 798-803, 2017, 2017.04. |
| 171. |
Masaoka H, Ito H, Gallus S, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population., Drug Alcohol Depend, 173: 85-91, 2017, 2017.04. |
| 172. |
Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress., Ann Oncol, 28 (3): 569-575, 2017, 2017.03. |
| 173. |
Tatsugami K, Yoshioka K, Shiroki R, Eto M, Yoshino Y, Tozawa K, Fukasawa S, Fujisawa M, Takenaka A, Nasu Y, Kashiwagi A, Gotoh M, Terachi T; Japanese Society of Endourology:, Reality of nerve sparing and surgical margins in surgeons' early experience with robot-assisted radical prostatectomy in Japan., Int J Urol, 24 (3): 191-196, 2017, 2017.03. |
| 174. |
Imada K, Shiota M, Kuroiwa K, Sugimoto M, Abe T, Kohashi K, Yokomizo A, Eto M, Naito S, Oda Y:, FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer., Prostate, 77 (2): 145-153, 2017, 2017.02. |
| 175. |
Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M:, Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor., J Urol, 197 (2): 308-313, 2017, 2017.02. |
| 176. |
Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, Bensalah K; members of the Kidney Cancer group of the CCAFU:, Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes., Urol Oncol, 35 (1): 35.e15-35.e19, 2017, 2017.01. |
| 177. |
Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M:, PD-L1 expression in papillary renal cell carcinoma., BMC Urol, 17 (1): 8, 2017, 2017.01. |
| 178. |
Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M, Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare., BJU Int, 118 (6): 880-884, 2016, 2016.12. |
| 179. |
Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T, C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy., Oncol Lett, 12 (5): 3995-4000, 2016, 2016.11. |
| 180. |
Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, Sasaki T, Nakamura K, Honda H, Eto M, Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer., Jpn J Clin Oncol, 46 (10): 952-957, 2016, 2016.10. |
| 181. |
Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Eto M, et al., Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan., J Infect Chemother, 22 (9): 581-586, 2016, 2016.09. |
| 182. |
Miyazato M, Oshiro T, Saito S, Takahashi R, Eto M, Nishi H, Fujimoto N, Sumino Y, Miyata H, Arai K, Kinjo T, Effects of switching from alpha-blocker to tadalafil in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (KYU-PRO STUDY)., Nishinihon J Urol, 78: 398-405, 2016, 2016.08. |
| 183. |
Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A, Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2., Cancer Sci, 107 (7): 1022-1028, 2016, 2016.07. |
| 184. |
Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K,, Nakamura T, Ogawa O, Naito S, Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy., Cancer Sci, 107 (7): 1013-1017, 2016, 2016.07. |
| 185. |
Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism., Prostate Cancer Prostatic Dis, 19 (2): 191-196, 2016, 2016.06. |
| 186. |
Masaoka H, Ito H, Soga N, Hosono S, Oze I, Watanabe M, Tanaka H, Yokomizo A, Hayashi N, Eto M, Matsuo K, Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction., Carcinogenesis, 37 (6): 583-588, 2016, 2016.06. |
| 187. |
Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y, Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer., Int Immunopharmacol, 35: 327-331, 2016, 2016.06. |
| 188. |
Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, et al., Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 46 (5): 468-474, 2016, 2016.05. |
| 189. |
Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M, Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma., Cancer Sci, 107 (5): 700-707, 2016, 2016.05. |
| 190. |
Inokuchi J, Seiji Naito, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C, Cancer Registration Committee of the Japanese Urological Association, Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association., Int J Urol, 23 (3): 224-230, 2016, 2016.03. |
| 191. |
Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, et al., The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery., World J Urol, 34 (3): 347-352, 2016, 2016.03. |
| 192. |
Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M, CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma., Oncol Lett, 11 (3): 1911-1916, 2016, 2016.03. |
| 193. |
Shiota M, Eto M, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer., Int J Urol, 23 (5): 360-369, 2016, 2016.03. |
| 194. |
Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A, Eto M, Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer., Anticancer Res, 36 (2): 799-802, 2016, 2016.02. |
| 195. |
Shiota M, Yokomizo A, Eto M, Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy., Front Oncol, 5 :304, 2016, 2016.01. |
| 196. |
Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K, An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy., Clin Cancer Res, 22 (1): 54-60, 2016, 2016.01. |
| 197. |
Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E, Hinotsu S, Cancer Registration Committee of the Japanese Urological Association, Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association., Int J Urol, 22 (11): 1013-1020, 2015, 2015.11. |
| 198. |
Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database., Int J Urol, 22 (11): 1023-1027, 2015, 2015.11. |
| 199. |
Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S, Japan RCC Trialist Collaborative Group (JRTCG) investigators, Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan., BMC Cancer, 15: 667, 2015, 2015.10. |
| 200. |
Kanayama HO, Fukumori T, Fujimoto H, Nakanishi H, Ohyama C, Suzuki K, Nishiyama H, Eto M, Miki T, Kamoi K, Kubota Y, Takahashi S, Homma Y, Naito S, Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association., Int J Urol, 22 (9): S1-S7, 2015, 2015.09. |
| 201. |
Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H, Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma., Ann Oncol, 26 (9): 1871-1876, 2015, 2015.09. |
| 202. |
Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S, Japanese Society of Renal Cancer, Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era., Int J Urol, 22 (8): 736-740, 2015 , 2015.08. |
| 203. |
Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M, Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells., Oncol Rep, 33 (6): 2947-2953, 2015, 2015.06. |
| 204. |
Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M, C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways., Oncol Rep, 33 (4): 1844-1850, 2015, 2015.04. |
| 205. |
Eto M, IJU this issue., Int J Urol, 22 (3): 241, 2015, 2015.03. |
| 206. |
Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai S, Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., Transpl Immunol, 32 (2): 131-139, 2015, 2015.03. |
| 207. |
Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA., C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells., Prostate, 57:66-79, 2003.09. |
| 208. |
Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW., Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions., J. Immunol, 169 (5): 2390-2396, 2002, 2002.09. |
| 209. |
Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, Nomoto K, Naito S., Antitumor activity of interleukin-12 against murine bladder cancer., J. Urol, 163 (5): 1549-1552, 2000
, 2000.05. |
| 210. |
Okano S, Eto M, Tomita Y, Yoshizumi T, Yamada H, Minagawa R, Nomoto K, Sugimachi K, Nomoto K., Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation., Transplantation, 71 (3): 447-456, 2001
, 2001.02. |
| 211. |
Omoto K, Y-Y Kong, Nomoto K, Umesue M, Murakami Y, Eto M, Nomoto K, Sensitization of T cell receptor-αβ+ T cells recovered from long-term T cell receptor-downmodulation., Immunology, 88: 230-237, 1996.06. |
| 212. |
Iwatsubo E, Sakamoto Y, Eto M, Kumazawa J, Role of the transversus perinei profundus muscle on voiding: the meaning of UPmax in patients with paralyzed urethral sphincter., Neurourol Urodyn, 15: 169-175, 1996.01. |
| 213. |
Nishimura Y, Eto M, Maeda T, Hiromatsu K, Nomoto K, Y-Y Kong, Nomoto K, The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system., Immunobiol, 193 (5): 420-438, 1995.08. |
| 214. |
Eto M, Nishimura Y, Matsuo K, Omoto K, Goto K, Kumazawa J, Nomoto K, Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats., J Urol, 153: 1693-1696, 1995.05. |
| 215. |
Maeda T, Eto M, T Lin, Nishimura Y, Y-Y Kong, Nomoto K, Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-T cell receptor antibody., J Immunol, 153: 4311-4320, 1994.11. |
| 216. |
Nishimura Y, Eto M, Maeda T, Hiromatsu K, Kobayashi N, Nomoto K, Y-Y Kong, Nomoto K, Inhibition of skin xenograft rejetion by depleting T-cell receptor αβ-bearing cells without T-cell receptor γδ-bearing cells or natural killer cells by monoclonal antibody., Immunology, 83: 196-204, 1994.10. |
| 217. |
Eto M, Nishimura Y, Y-Y Kong, Maeda T, Nomoto K, Kumazawa J, Nomoto K, Importance of intrathymic mixed chimerism for maintenace of skin allograft tolerance aross fully allogeneic (entire major H-2 plus multiminor histocompatibility) antigen barriers in mice., Transplant Proc, 26 (2): 841-844, 1994.04. |
| 218. |
Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, Nomoto K, Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody., Arthritis & Rheumatism, 37 (3): 406-413, 1994.03. |
| 219. |
Maeda T, Eto M, Nishimura Y, Y-Y Kong, Nomoto K, Nomoto K, Evidence that donor-specific suppressor T cells can be produced indepently of the thymus., Transplantation, 57 (3): 461-463, 1994.02. |
| 220. |
Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Y-Y Kong, Kubo RT, Kumazawa J, Nomoto K, Inhibition of allograft rejection by anti-T-cell receptor-αβ monoclonal antibodies preserving resistance to bacterial infection., Immunology, 81: 198-204, 1994.02. |
| 221. |
Maeda T, Eto M, Nishimura Y, Nomoto K, Y-Y Kong, Nomoto K, Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice., J Immunol, 150 (3): 753-762, 1993.02. |
| 222. |
Maeda T, Eto M, Nishimura Y, Nomoto Y, Y-Y Kong, Nomoto K, Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming., Immunology, 78: 113-121, 1993.01. |
